Ovidiu Vasile Fabian

Dr. Ovidiu Vasile Fabian

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2004 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
ERE. Ryschich
E. Ryschich
OCO. Cebotari
O. Cebotari
OFOvidiu Vasile Fabian
Ovidiu Vasile Fabian
FAF. Autschbach
F. Autschbach
Jörg KleeffJörg Kleeff
Jörg Kleeff
JSJ. Schmidt
J. Schmidt

1 June 2009
Verified
Journal Article
Closed access
VMVALENTIN MUNTEAN
VALENTIN MUNTEAN
AMAnca Mihailov
Anca Mihailov
CICornel Iancu
Cornel Iancu
RTRazvan Toganel
Razvan Toganel
OFOvidiu Vasile Fabian
Ovidiu Vasile Fabian
MMMaximilian Vlad Muntean
Maximilian Vlad Muntean

21 August 2013
Verified
Journal Article
Closed access
VMV Muntean
V Muntean
IDI Domsa
I Domsa
AZA Zolog
A Zolog
DPDoina Piciu
Doina Piciu
OFOvidiu Vasile Fabian
Ovidiu Vasile Fabian
MMM V Muntean
M V Muntean

17 January 2013 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
NSNicolae Irinel Simion
Nicolae Irinel Simion
VMValentin Muntean
Valentin Muntean
OFOvidiu Vasile Fabian
Ovidiu Vasile Fabian
More than 60% of neuroendocrine tumours, also called carcinoids, are localised within the gastrointestinal tract. Small bowel neuroendocrine tumours have been diagnosed with increasing frequency over the past 35 years, being the second most frequent tumours of the small intestine. Ileal neuroendocrine tumours diagnosis is late because patients have non-specific symptoms. We have proposed to illustrate as an example the case of a patient, and on its basis, to make a brief review of the literature on small bowel neuroendocrine tumours, resuming several recent changes in the field, concerning classification criteria of these tumours and new recommendations and current advances in diagnosis and treatment. This patient came to our emergency department with a complete bowel obstruction, along with a 2-year history of peristaltic abdominal pain, vomits and diarrhoea episodes. During emergency laparotomy, an ileal stricture was observed, that showed to be a neuroendocrine tumour of the small bowel.

28 September 2004 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EREduard Ryschich
Eduard Ryschich
RJRalf Jesnowski
Ralf Jesnowski
JRJörg Ringel
Jörg Ringel
WHWalter Harms
Walter Harms
OFOvidiu Vasile Fabian
Ovidiu Vasile Fabian
MLMatthias Löhr
Matthias Löhr
Local therapy of pancreatic cancer with microencapsulated CYP2B1‐producing cells and ifosfamide showed an effect both on the primary tumor and on distant metastatases. This possibly represents a consequence of the activation of immune response. Other studies have demonstrated that local tumor irradiation leads to the activation of the intratumoral lymphocyte infiltration. The aim of our study was to investigate the efficacy of the combined therapy with low‐dose irradiation, ifosfamide and CYP2B1‐producing cells. Syngenic pancreatic cancer was induced in 38 Lewis‐rats by subcutaneous inoculation of 1 × 106 (DSL6A) tumor cells. Microencapsulated CYP2B1‐producing cells were injected peritumorally 10–‐12 weeks after tumor implantation. Animals were randomized to the following groups: 1) control (NaCl, 1 ml i.p.), 2) ifosfamide (50 mg/kg, i.p., (3×/week), 3) local irradiation with 5 Gy and 4) ifosfamide plus irradiation. The tumor growth was monitored for 3 weeks. The tumor infiltration with CD4+, CD8+, NK‐cells, microvessel density and proliferation rates were investigated by immunohistochemistry. Cytokine plasma level for TNF‐α were measured by ELISA. Seven of 9 animals in the group of combined therapy showed an objective response to the therapy. The therapy with ifosfamide or radiation alone showed 5 and 3 responders, respectively. The mean tumor volume was significantly reduced after combined ifosfamide plus radiation therapy in the first week, whereas monotherapy with ifosfamide or radiation significantly decreased tumor growth earliest after 2 and 3 weeks, respectively. The high plasma level of TNF‐α in the control group was significantly reduced after combined ifosfamide/irradiation treatment. The lymphocyte infiltration and tumor proliferation were not significantly different between the groups. Microvascular density was significantly increased after ifosfamide and ifosfamide plus irradiation therapy. The combination of ifosfamide/CYP2B1‐producing cells and irradiation showed an earlier therapeutical effect on the growth of rat pancreatic cancer than the irradiation or ifosfamide alone. There was no evidence of late activation of lymphocyte infiltration and PCNA‐positive tumor cells.

1 December 2009
Verified
Journal Article
Closed access
VMVALENTIN MUNTEAN
VALENTIN MUNTEAN
TOTraian Oniu
Traian Oniu
CLCorneliu Lungoci
Corneliu Lungoci
OFOvidiu Vasile Fabian
Ovidiu Vasile Fabian
DMDoru Munteanu
Doru Munteanu
VBVasile Bintintan
Vasile Bintintan